||Based on LOCF analysis of data from all treated
subjects, those receiving placebo demonstrated statistically significant
(P<=0.05) mean increases from baseline in A1c. In patients receiving ACTOS,
the mean decrease in A1c from baseline was statistically significant
(P<=0.05), with the exception of the 7.5-mg group, at most timepoints. The
difference in mean A1c at endpoint for the 45-mg once-daily dose group vs
placebo was 1.6 percentage points.
Aronoff S, et al. Diabetes Care. 2000;23:1605-1611.